Displaying 1 actively recruiting clinical trial nationwide with the keyword(s) "Alstrom Syndrome"
|Study Name||Sponsor||Status||Trial Phase||Quota||Distance|
|A Phase 3 Trial of Setmelanotide (RM-493), a Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Patients With Moderate to Severe Obesity||Rhythm Pharmaceuticals, Inc.||Recruiting||363 miles|
Listings display only those clinical trials that have locations in the USA. Distances calculated are an approximation only.